Valuation: Gilead Sciences, Inc.

Market Cap 18TCr 16TCr 15TCr 13TCr 25TCr 17,40000Cr 25TCr 1,77300Cr 68TCr 8,82700Cr 68TCr 67TCr 28,06300Cr P/E 2026 *
-44.3x
P/E 2027 * 18.2x
Enterprise Value 20TCr 17TCr 16TCr 15TCr 28TCr 19,00500Cr 28TCr 1,93600Cr 75TCr 9,64100Cr 74TCr 73TCr 30,65100Cr EV / Sales 2026 *
6.46x
EV / Sales 2027 * 5.83x
Free-Float
99.88%
Yield 2026 *
2.25%
Yield 2027 * 2.29%
1 day-0.05%
1 week-0.95%
Current month-1.13%
1 month+4.75%
3 months+16.25%
6 months-1.63%
Current year+17.79%
1 week 123.68
Extreme 123.68
125.88
1 month 118.74
Extreme 118.74
130
Current year 100.42
Extreme 100.42
132
1 year 93.42
Extreme 93.42
132
3 years 57.58
Extreme 57.58
132
5 years 52.23
Extreme 52.23
132
10 years 46.23
Extreme 46.23
132
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-0.95% - - 18TCr
+0.52%+2.38%+53.79%+99.89% 1,01500Cr
-2.04%-2.32%+48.19%+62.83% 64TCr
-1.33%+4.00%+18.90%+70.09% 46TCr
-1.43%+1.88%+37.14%+36.64% 35TCr
-1.21%+1.38%+16.06%+22.85% 26TCr
-1.52%+0.59%+4.66%+9.20% 25TCr
-1.40%-3.95%+37.63%+44.85% 21TCr
-1.39%-5.10%-21.97%-58.42% 19TCr
-1.71%-1.52%+28.32%+90.84% 18TCr
Average -1.16%-3.35%+24.75%+42.08% 39.67TCr
Weighted average by Cap. -0.95%-2.21%+34.03%+58.81%

Financials

2026 *2027 *
Net sales 3.07TCr 2.66TCr 2.51TCr 2.28TCr 4.27TCr 2,94300Cr 4.3TCr 30TCr 12TCr 1,49300Cr 12TCr 11TCr 4,74600Cr 3.27TCr 2.83TCr 2.67TCr 2.42TCr 4.55TCr 3,13200Cr 4.58TCr 32TCr 12TCr 1,58900Cr 12TCr 12TCr 5,05200Cr
Net income -427.47Cr -370.4Cr -349.55Cr -317.11Cr -594.88Cr -41TCr -599.19Cr -4.17TCr -1.61TCr -21TCr -1.61TCr -1.57TCr -66TCr 1.03TCr 890.33Cr 840.21Cr 762.24Cr 1.43TCr 98TCr 1.44TCr 10TCr 3.87TCr 50TCr 3.86TCr 3.77TCr 1,58800Cr
Net Debt 1.67TCr 1.45TCr 1.37TCr 1.24TCr 2.33TCr 1,60500Cr 2.35TCr 16TCr 6.3TCr 81TCr 6.29TCr 6.15TCr 2,58800Cr 912.45Cr 790.64Cr 746.13Cr 676.89Cr 1.27TCr 87TCr 1.28TCr 8.91TCr 3.43TCr 44TCr 3.43TCr 3.35TCr 1,41000Cr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
15/26/15 124.46 +0.35% 130
14/26/14 €124.02 -0.58% 25
11/26/11 €124.74 +0.86% 0
10/26/10 €123.68 -1.31% 145
09/26/09 €125.32 -0.27% 150
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
146.41USD
Average target price
158.15USD
Spread / Average Target
+8.02%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!